Global Medical Radioactive Iodine I-131 Market Growth (Status and Outlook) 2024-2030

Global Medical Radioactive Iodine I-131 Market Growth (Status and Outlook) 2024-2030

Radioactive iodine (I-131),an isotope of iodine that emits radiation, is used for medical purposes. When a small dose of I-131 is swallowed, it is absorbed into the bloodstream in the gastrointestinal (GI) tract. It is concentrated from the blood by the thyroid gland, where it begins destroying the gland's cells. This report mainly focuses on medical radioactive iodine I-131 market.

The global Medical Radioactive Iodine I-131 market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Medical Radioactive Iodine I-131 Industry Forecast” looks at past sales and reviews total world Medical Radioactive Iodine I-131 sales in 2022, providing a comprehensive analysis by region and market sector of projected Medical Radioactive Iodine I-131 sales for 2023 through 2029. With Medical Radioactive Iodine I-131 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medical Radioactive Iodine I-131 industry.

This Insight Report provides a comprehensive analysis of the global Medical Radioactive Iodine I-131 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Medical Radioactive Iodine I-131 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Medical Radioactive Iodine I-131 market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medical Radioactive Iodine I-131 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medical Radioactive Iodine I-131.

United States market for Medical Radioactive Iodine I-131 is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Medical Radioactive Iodine I-131 is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Medical Radioactive Iodine I-131 is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Medical Radioactive Iodine I-131 players cover NTP Radioisotopes, Jubilant DraxImage, ROSATOM, Polatom, Nordion, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Medical Radioactive Iodine I-131 market by product type, application, key players and key regions and countries.

Segmentation by Type:
Capsule
Solution

Segmentation by Application:
Treatment
Medical Imaging

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Capsule
Solution

Segmentation by Application:
Treatment
Medical Imaging

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
NTP Radioisotopes
Jubilant DraxImage
ROSATOM
Polatom
Nordion
IRE ELIT

Please note: The report will take approximately 2 business days to prepare and deliver.